Literature DB >> 16968892

Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance.

Anil K Bidani1, Maria Picken, Rifat Hacioglu, Geoffrey Williamson, Karen A Griffin.   

Abstract

The rat streptozotocin (STZ)-induced diabetes model is widely used to investigate the pathogenesis of diabetic nephropathy. However, overt nephropathy is inexplicably slow to develop in this model compared with renal mass reduction (RMR) models. To examine whether blood pressure (BP) differences correlated with the time course of glomerulosclerosis (GS), BP was measured continuously throughout the course by radiotelemetry in control (n = 17), partially insulin-treated STZ-diabetes (average blood glucose 364 +/- 15 mg/dl; n = 15), and two normotensive RMR models (systolic BP <140 mmHg)--uninephrectomy (UNX; n = 16) and 3/4 RMR by surgical excision [right nephrectomy + excision of both poles of left kidney (RK-NX); n = 12] in Sprague-Dawley rats. Proteinuria and GS were assessed at approximately 16-20 wk (all groups) and at 36-40 wk (all groups except RK-NX). At 16 wk, significantly greater proteinuria and GS had developed in the RK-NX group compared with the other three groups (not different from each other). By 36-40 wk, substantial proteinuria and GS had also developed in the UNX group, but both the control and the STZ-diabetic rats exhibited comparable modest proteinuria and minimal GS. Systolic BP (mmHg) was significantly reduced in the STZ-diabetic rats (116 +/- 1.1) compared with both control (124 +/- 1.0) and RMR (128 +/- 1.2 and 130 +/- 3.0) groups (P < 0.01). Similarly, "BP load" as estimated by BP power spectral analysis was also lower in the STZ-diabetic rats. Given the known protective effects of BP reductions on the progression of diabetic nephropathy, it is likely that this spontaneous reduction in ambient BP contributes to the slow development of GS in the STZ-diabetes model compared with the normotensive RMR models.

Entities:  

Mesh:

Year:  2006        PMID: 16968892      PMCID: PMC1794259          DOI: 10.1152/ajprenal.00017.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  65 in total

1.  Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass.

Authors:  W M Deen; D A Maddox; C R Robertson; B M Brenner
Journal:  Am J Physiol       Date:  1974-09

2.  Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson): report of a case.

Authors:  J Berkman; H Rifkin
Journal:  Metabolism       Date:  1973-05       Impact factor: 8.694

Review 3.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

4.  Glomerular hemodynamics in experimental diabetes mellitus.

Authors:  T H Hostetter; J L Troy; B M Brenner
Journal:  Kidney Int       Date:  1981-03       Impact factor: 10.612

5.  The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat.

Authors:  S M Mauer; M W Steffes; S Azar; S K Sandberg; D M Brown
Journal:  Diabetes       Date:  1978-07       Impact factor: 9.461

6.  Blood pressure lability and glomerulosclerosis after normotensive 5/6 renal mass reduction in the rat.

Authors:  Karen A Griffin; Maria M Picken; Anil K Bidani
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

Review 7.  Pathophysiology of hypertensive renal damage: implications for therapy.

Authors:  Anil K Bidani; Karen A Griffin
Journal:  Hypertension       Date:  2004-09-27       Impact factor: 10.190

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Low protein diet mediated renoprotection in remnant kidneys: Renal autoregulatory versus hypertrophic mechanisms.

Authors:  Karen A Griffin; Maria Picken; Anita Giobbie-Hurder; Anil K Bidani
Journal:  Kidney Int       Date:  2003-02       Impact factor: 10.612

10.  "Step" vs. "dynamic" autoregulation: implications for susceptibility to hypertensive injury.

Authors:  Anil K Bidani; Rifat Hacioglu; Isam Abu-Amarah; Geoffrey A Williamson; Rodger Loutzenhiser; Karen A Griffin
Journal:  Am J Physiol Renal Physiol       Date:  2003-03-11
View more
  18 in total

1.  βENaC acts as a mechanosensor in renal vascular smooth muscle cells that contributes to renal myogenic blood flow regulation, protection from renal injury and hypertension.

Authors:  Heather A Drummond; David E Stec
Journal:  J Nephrol Res       Date:  2015-06-26

2.  Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities.

Authors:  Gursev S Dhaunsi; Mariam H M Yousif; Saghir Akhtar; Mark C Chappell; Debra I Diz; Ibrahim F Benter
Journal:  Eur J Pharmacol       Date:  2010-05-04       Impact factor: 4.432

3.  Extended longitudinal analysis of arterial pressure and heart rate control in unanesthetized rats with type 1 diabetes.

Authors:  Chikodi N Anigbogu; Richard O Speakman; Dennis L Silcox; Laura V Brown; David R Brown; Ming C Gong; Abhijit R Patwardhan; L Raymond Reynolds; Dennis G Karounos; Don E Burgess; Bobby R Baldridge; David C Randall
Journal:  Auton Neurosci       Date:  2012-07-17       Impact factor: 3.145

4.  Blood pressure-renal blood flow relationships in conscious angiotensin II- and phenylephrine-infused rats.

Authors:  Aaron J Polichnowski; Karen A Griffin; Jianrui Long; Geoffrey A Williamson; Anil K Bidani
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-03

Review 5.  The renal vascular response to diabetes.

Authors:  Pamela K Carmines
Journal:  Curr Opin Nephrol Hypertens       Date:  2010-01       Impact factor: 2.894

6.  Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice.

Authors:  Jussara M do Carmo; Lakshmi S Tallam; John V Roberts; Elizabeth L Brandon; John Biglane; Alexandre A da Silva; John E Hall
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-15       Impact factor: 3.619

7.  Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes.

Authors:  Olaf Brouwers; Petra M G Niessen; Toshio Miyata; Jakob A Østergaard; Allan Flyvbjerg; Carine J Peutz-Kootstra; Jonas Sieber; Peter H Mundel; Michael Brownlee; Ben J A Janssen; Jo G R De Mey; Coen D A Stehouwer; Casper G Schalkwijk
Journal:  Diabetologia       Date:  2013-10-26       Impact factor: 10.122

8.  Increased susceptibility to hypertensive renal disease in streptozotocin-treated diabetic rats is not modulated by salt intake.

Authors:  C A Sima; M P Koeners; J A Joles; B Braam; A B Magil; W A Cupples
Journal:  Diabetologia       Date:  2012-05-06       Impact factor: 10.122

Review 9.  Renal microvascular dysfunction, hypertension and CKD progression.

Authors:  Anil K Bidani; Aaron J Polichnowski; Rodger Loutzenhiser; Karen A Griffin
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-01       Impact factor: 2.894

10.  Endogenous angiotensin-(1-7) reduces cardiac ischemia-induced dysfunction in diabetic hypertensive rats.

Authors:  May Al-Maghrebi; Ibrahim F Benter; Debra I Diz
Journal:  Pharmacol Res       Date:  2008-12-31       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.